Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Xencor Inc (XNCR)

Xencor Inc (XNCR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,031,875
  • Shares Outstanding, K 71,410
  • Annual Sales, $ 110,490 K
  • Annual Income, $ -232,620 K
  • EBIT $ -120 M
  • EBITDA $ -121 M
  • 60-Month Beta 0.97
  • Price/Sales 7.11
  • Price/Cash Flow N/A
  • Price/Book 1.59

Options Overview Details

View History
  • Implied Volatility 218.32% (+7.46%)
  • Historical Volatility 57.16%
  • IV Percentile 76%
  • IV Rank 42.61%
  • IV High 440.78% on 09/10/25
  • IV Low 53.12% on 08/18/25
  • Expected Move (DTE 1) 5.27 (39.89%)
  • Put/Call Vol Ratio 0.67
  • Today's Volume 10
  • Volume Avg (30-Day) 14
  • Put/Call OI Ratio 0.20
  • Today's Open Interest 1,099
  • Open Int (30-Day) 1,119
  • Expected Range 7.94 to 18.48

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 15 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.64
  • Number of Estimates 7
  • High Estimate -0.10
  • Low Estimate -0.95
  • Prior Year -0.62
  • Growth Rate Est. (year over year) -3.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.19 +0.15%
on 01/15/26
16.92 -21.93%
on 12/16/25
-3.58 (-21.32%)
since 12/15/25
3-Month
12.16 +8.59%
on 10/23/25
18.69 -29.32%
on 12/05/25
-0.89 (-6.31%)
since 10/15/25
52-Week
6.92 +90.90%
on 08/11/25
21.00 -37.10%
on 01/23/25
-6.84 (-34.11%)
since 01/15/25

Most Recent Stories

More News
Xencor Highlights Corporate Priorities and 2026 Pipeline Milestones

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced corporate priorities and 2026...

XNCR : 13.21 (-8.58%)
Xencor Announces Extension of U.S. Patent Term on Certain Xtendâ„¢ Antibodies

-- Royalty term on Ultomiris® sales in the United States anticipated to continue into year-end 2028, extending term by three years -- -- Additional $100 million to $120 million in potential royalty...

XNCR : 13.21 (-8.58%)
Xencor to Participate at Upcoming Investor Conferences

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today announced that company management will...

XNCR : 13.21 (-8.58%)
Xencor: Q3 Earnings Snapshot

Xencor: Q3 Earnings Snapshot

XNCR : 13.21 (-8.58%)
Xencor Reports Third Quarter 2025 Financial Results

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the third...

XNCR : 13.21 (-8.58%)
Xencor Presents Initial Data for XmAb819, a First-in-class ENPP3 x CD3 Bispecific T-Cell Engager, in Development for Clear Cell Renal Cell Carcinoma

-- XmAb819 is well-tolerated in heavily pretreated patients with advanced ccRCC -- -- 25% overall response rate (ORR) observed within the target dose range -- -- First dose-expansion...

XNCR : 13.21 (-8.58%)
Xencor to Host Webcast and Conference Call to Discuss Initial Results from the Ongoing Phase 1 Dose-Escalation Study of XmAb819 in Advanced Clear Cell Renal Cell Carcinoma

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, will host a conference call and webcast on Friday,...

XNCR : 13.21 (-8.58%)
Xencor (XNCR) Gets a Buy from Cantor Fitzgerald

In a report released yesterday, Steven Seedhouse from Cantor Fitzgerald maintained a Buy rating on Xencor, with a price target of $40.00. The company’s shares opened today at $13.95.Elevate Your Investing...

XNCR : 13.21 (-8.58%)
Longevity Biotech Surges as $72.6B Market Forecast Sparks Investment Rush

Issued on behalf of Avant Technologies Inc. VANCOUVER – Baystreet.ca News Commentary – The longevity and cell therapy sector has captured Wall Street's attention as market projections hit $72.6...

AUTL : 1.4400 (+1.41%)
AVAI : 0.7770 (+12.80%)
DNLI : 18.78 (+2.79%)
EDIT : 2.09 (-5.86%)
XNCR : 13.21 (-8.58%)
Bank of America Securities Reaffirms Their Hold Rating on Xencor (XNCR)

Bank of America Securities analyst Alec Stranahan reiterated a Hold rating on Xencor today and set a price target of $14.00. The company’s shares closed yesterday at $13.96.Elevate Your Investing Strategy:...

XNCR : 13.21 (-8.58%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 24% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Xencor Inc. is a clinical-stage biopharmaceutical company. It develops antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer. Xencor Inc. is based in Monrovia, California.

See More

Key Turning Points

3rd Resistance Point 15.64
2nd Resistance Point 15.14
1st Resistance Point 14.18
Last Price 13.21
1st Support Level 12.72
2nd Support Level 12.22
3rd Support Level 11.26

See More

52-Week High 21.00
Fibonacci 61.8% 15.62
Fibonacci 50% 13.96
Last Price 13.21
Fibonacci 38.2% 12.30
52-Week Low 6.92

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar